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Apoptosis, cell proliferation and expression of Bcl12 and
Bax in gastric carcinomas: immunohistochemical and
clinicopathological study
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Department of Pathology, School of Medicine, Kitasato University, 1-15-1 Kitasato, Sagamihara, Kanagawa 228, Japan
Summary To clarify the relation between bcl-2 and baxprotein (Bcl-2 and Bax) expression with regard to apoptosis and cell proliferation, 82
gastric carcinomas were immunohistochemically investigated. The significance of apoptosis for biological behaviour of the tumours was also
examined. The apoptotic indices (Als) were significantly lower in early-stage than in advanced-stage lesions (P<0.05), being positively
correlated with the mitotic indices (MIs) (r=0.447, P<0.001). No association between eitherAls or Mls and tumour size (diameter of intramural
spreading) was noted. The Als in the high Bcl-2-immunoreactive score group were significantly smaller than in either the low or the negative
categories, whereas they were relatively elevated in the high Bax score group. In addition, an inverse correlation between Bcl-2 and Bax
expression was revealed for both Als and MIs. Although depth of tumour invasion and lymph node status were clearly associated with
favourable outcome, no relation between survival rates and average values of either Als or MIs, or immunoreactive scores for Bcl-2 and
Bax was observed. These results indicate that in gastric carcinomas, apoptosis is closely associated with cell proliferation and expression of
Bcl-2 and Bax, but appears likely to have no particular biological significance as a prognostic factor.
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Analysis of the balance between cell proliferation and loss by
death is essential for assessment of tissue kinetics. It is widely
accepted that apoptosis, with its characteristic nuclear and cyto-
plasmic features, plays an important role in cell deletion, espe-
cially during embryogenesis. For example, naturally occurring
neuronal death during neurogenesis and negative selection of T
lymphocytes in the thymus are achieved by apoptosis (Shi et al,
1989; Smith et al, 1989). Recently, several studies have docu-
mented a possible role ofapoptosis in the development or progres-
sion of malignant neoplasms, including cervical (Shoji et al,
1996), oesophageal (Ohbu et al, 1995) and colorectal tumours
(Ikenaga et al, 1996). Our previous study demonstrated a close
correlation between the susceptibility to apoptosis and eitherdepth
of tumour invasion or histological differentiation in gastric carci-
nomas (Saegusa et al, 1995a). However the significance of apop-
tosis in clinicopathological behaviour (as a prognostic factor) still
remains to be determined.
The bcl-2 proto-oncogene, discovered at the t(14;18) chromo-
somal breakpoint in human follicular lymphomas and B-cell
leukaemias, is a member of the group of molecules related to
apoptosis, its expression being able to inhibit the process of this
form of single-cell death (Tsujimoto et al, 1984). It has been
proposed that there is a new category of oncogenes, linked to the
bcl-2 gene as extended cell survival, [suppression of apoptosis
due to bcl-2 protein (Bcl-2) expression] may prove to be a key
event that increases the opportunity to acquire additional genetic
defects in proliferation-associated or tumour-suppressor genes
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(Korsmeyer, 1992). The bcl-2-associated X protein (Bax), in
contrast, has been demonstrated to accelerate cell death after
an apoptotic stimulus, by forming heterodimers with Bcl-2
(Krajiewski et al, 1994). Little is known of the relationship
between Bcl-2 and Bax expression in human malignant tumours
and therefore, in the present study, we investigated this point and
its significance for apoptosis and cell proliferation in a series of
human gastric carcinomas. In addition, the clinicopathological
relevance ofapoptosis to biological behaviour was examined.
MATERIALS AND METHODS
Cases
A total of 82 gastric carcinoma cases surgically resected at the
Kitasato University Hospital during 1988 to 1994 were investi-
gated. All the tissues were fixed in 10% buffered formalin and
embedded in paraffin wax. Histopathological assessment was
performed according to the criteria of Sugano et al (1982): well-
differentiated and moderately differentiated adenocarcinomas
were included in the differentiated category and poorly differenti-
ated adenocarcinomas and signet-ring cell carcinomas were in the
undifferentiated type. With this classification, the investigated
series comprised 58 cases of the differentiated type and 24 of the
undifferentiated type. Both types were subclassified into two
groups according to the depth of invasion, 40 cases ofearly-stage
lesions demonstrating invasion of the mucosa and/or submucosa
and 42 cases ofadvanced stage exhibiting invasion into or through
the muscularis propria.
Of 82 gastric carcinomas, we were able to analyse 78 cases for
outcome after surgery with a mean follow-up time of 30 months
(range 1-93 months). None of the cases had been treated by
chemotherapy or radiotherapy before gastrectomy. Sixty-four
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Figure 1 Apoptotic and mitotic figures. Apoptotic cells show homogeneous
condensed nuclei with nuclear fragments (apoptotic bodies) in cancer lesions
(indicated by long arrows). Mitotic findings are also noted (indicated by short
arrows). (A) Differentiated-type carcinoma (H&E stain, original magnification
x 640). (B) Undifferentiated-type (H&E stain, original magnification x 640)
cases (26 early and 38 advanced carcinomas) had been treated
with tegafur for at least 3 years, also having received 2-4 cycles of
mitomycin C and fluorouracil in advanced cases, whereas 14 cases
(11 early and three advanced carcinomas) had received no
chemotherapy or radiotherapy.
Apoptotic and mitotic indices (Al and MI)
Detection of apoptotic cells was performed using haematoxylin
andeosin-stained sections underhigh-power view (10 x ocular and
40 x objective), in accordance with the criteria ofKerr et al (1972)
as follows: overall shrinkage and homogeneously dark basophilic
nuclei; presence of nuclear fragments (apoptotic bodies); sharply
delineated cell borders surrounded by empty space; and homo-
geneous eosinophilic cytoplasm (Figure 1).
The slides were moved randomly and ten adjacent fields ofeach
cancer were selected; areas of severe inflammation and necrotic
foci were excepted because of the difficulty in distinguishing
single apoptotic cells in such cases. AIs were then calculated after
counting at least 3000 tumour nuclei for each case. MIs were also
estimated in a similar manner.
Immunohistochemistry and scoring method
Immunohistochemical staining for Bcl-2 (x 100 diluted anti-
human Bcl-2 mouse monoclonal antibody, Dako, Copenhagen,
Denmark) and Bax (x 800 diluted anti-Bax (pl9) rabbit poly-
clonal antibody, Santa Cruz Bio., Santa Cruz, CA, USA) was
performed using a combination of microwave-oven heating and
the streptavidin-peroxidase complex [Histofine SAB-PO(M) kit,
Nichirei, Tokyo, Japan] method as previously described (Saegusa
et al, 1995b). To confirm the immunospecificity, immunohisto-
chemistry was performed in duplicate with sections processed
separately.
The immunostaining intensity of Bcl-2 and Bax was divided
into five groups, according to the classification of Sinicrope et al
(1995), with minor modifications as follows: 0, completely nega-
tive; 1+, very weak; 2+, weak; 3+, moderate; 4+, intense. For this
purpose the appropriate value for the majority of stained cells
was adopted. Percentages of positive tumour cells were classified
into four categories as follows: 1, less than 5%; 2, < 20%; 3,
20-50%; 4, over 50%. Immunoreactive scores for each tumour
case were calculated by multiplication of the values for the two
parameters. Lymphocytes and small vessels in each tumour
section were used as positive controls forBcl-2 and Bax immuno-
reactivity respectively. These immunostaining intensities were
designated as 4+.
Statistics
To analyse the correlation among AIs, MIs and Bcl-2 and Bax
immunoreactivity in gastric carcinomas, the Mann-Whitney U-
test and the Pearson's correlation coefficient were used, consid-
ering pathological factors, including tumour differentiation, depth
of invasion and size (lateral spreading diameter). Survival was
measured from the time of primary operation and survival curves
were generated by the methods of Kaplan and Meier (1958). The
log-rank test and Cox proportional hazards modelling were
performed to compare survival rates between subgroups classified
for various factors, including tumour stage, lymph node status,
AIs, MIs and Bcl-2 and Bax immunoreactivity. In addition, rela-
tion to lymph node status with or without Bcl-2 or Bax positivity
was analysed by the chi-square linear test. The cut-off for statis-
tical significance was defined as P <0.05.
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Figure 3 (A) Correlation between Als and Mls in gastric carcinomas. (B)
Correlation between tumour intramural spreading diameters and Als and MIs
RESULTS
Findings for apoptotic cells
Apoptotic cells exhibited a single round nuclei with homoge-
neously condensed chromatin together with marked eosinophilic
condensation of cytoplasm and were separated from their neigh-
bours by a clear halo (Figure 1). These morphologically character-
istic cells were found sporadically in cancer foci and were not
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Figure 4 Serial sections illustrating results of Bcl-2 and Bax immunohistochemistry through gastric carcinomas. (A-C) Bcl-2- and Bax-positive case (A)
Differentiated-type adenocarcinoma(H&E stain original magnification x 400). (B) Semiserial section to A showing strong Bax forgranular homogeneous
cytoplasmic staining (anti-Bax, original magnification x 400). (C) In the same field, only weak Bcl-2 immunoreactivity is evident in perinuclear locations and the
cytoplasm, whereas lymphocytes (indicated by arrow) show strong positivity (anit-Bcl-2, original magnification x 400). (D-F) Bcl-2-positive but Bax-negative
case. (D) Differentiated type adenocarcinoma (H&E stain original magnification x 400). (E) No apparent immunoreactivity for Bax (original magnification x 400). (F) In contrast to E, strong Bcl-2 immunoreactivity is noted in some areas (original magnification x 400). (G-1) Bcl-2-negative but Bax-positive case. (G)
Differentiated type adenocarcinoma (H&E stain original magnification x 400). (H) Granular Bax immunoreactivity is apparent in the cytoplasm of carcinoma cells
(original magnification x 400). (1) Bcl-2 immunopositivity is demonstrated by infiltrating lymphocytes (indicated by arrow) but not carcinoma cells, (original
magnification x 400)
frequently associated with severe inflammation and necrosis,
while being rare in normal gastric epithelium. Although differenti-
ation between apoptotic cells and small lymphocytes infiltrating
the tumour lesions was occasionally difficult, a chromatin pattern
was generally discernible in the latter and their scant cytoplasm
was useful for distinguishing them from apoptotic cells as
described previously (Aihara et al, 1994).
0.95 ± 0.4 and 1.16 ± 0.33% respectively. The values for early-
stage and differentiated-type lesions were statistically lower
than for the advanced and undifferentiated categories (Figure 2,
P <0.05 respectively).
Pearson's correlation coefficient analysis revealed a close corre-
lation between AIs and MIs (Figure 3A, r =0.447, P <0.001), but
there was no association between either AIs or MIs and tumour
size (lateral spreading diameter) (Figure 3B).
Relation between Als and Mis
The AIs ofearly- or advanced-stage carcinomas and differentiated
or undifferentiated types were 1.12 ± 0.45% (mean ± s.d.), 1.28 +
0.33%, 1.18 ± 0.42% and 1.26 ± 0.33% respectively. The early-
stage value was significantly lower than that for advanced-stage
lesions (P <0.05), whereas no correlation with tumour differentia-
tion was found (Figure 2).
The MIs for early- or advanced-stage carcinomas and differenti-
ated or undifferentiated types were 0.92 ± 0.42%, 1.09 ± 0.34%,
Relation among Als, MIs and expression of BcI-2
and Bax
Bcl-2 immunoreactivity was found throughout the cytoplasm, with
some concentration in the perinuclear zone, in tumour cells. The
intensity of immunostaining and the distribution of positive cells
were heterogeneous (Figure 4F). The differentiation of Bcl-2
immunoreactivity between lymphocytes infiltrating into epithe-
lium and tumour cells was not difficult as the former were usually
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Figure 5 (A) Relation between Bcl-2 immunoreactive scores and either Als or MIs in gastric carcinomas. The data are mean ± s.d. values. 1, The overall data;
2, in the early-stage category; 3, in the advanced stage. (B) Relation between Bax immunoreactive scores and either Als or Mls in gastric carcinomas. The data
are means ± s.d. values. 1, The overall data; 2, in early stage category; 3 in advanced stage. (C) The overall data for correlation between both immunopositivity
and either Als and Mls. The data are means ± s.d. values. CZ, Al (%); Ml (%)
small in comparison with the latter. Immunoreactivity (immunore-
active scores 21) was noted for 35 of 82 (42.7%) cases, with an
average value of8 ±4 (mean ± s.d. range 0-16). High Bcl-2 scores
(29) were found in 8 of 40 (20%) early- and 3 of 42 (7.1%)
Table 1 Relation between lymph node status and finding for Al, Ml, Bcl-2
and Bax in gastric carcinomas
Lymph node metastasis
Positive (n=46) Negative (n=32) P-value
Apoptotic index (%) 1.25 + 0.43 1.17 ± 0.34 NS
Mitotic index (%) 1.02 + 0.39 1.04 ± 0.39 NS
Bcl-2 score
0 21 (45.7%) 19 (59.4%)
1-8 16 (34.8%) 9 (28.1%)
9-16 9 (20.0%) 4 (12.5%) NS
Bax score
0 20 (43.5%) 19 (59.4%)
1-8 12 (26.1%) 4 (12.5%)
9-16 14 (30.4%) 9 (28.1%) NS
Early stage 9 (19.6%) 27 (84.3%)
Advanced stage 37 (80.4%) 5 (15.6%) P=0.0001
Al, apoptotic index; Ml, mitotic index; NS, not significant.
advanced-stage lesions, and 11 of 58 (19.0%) differentiated and
3 of 24 (12.5%) undifferentiated types. The overall Al for the high
Bcl-2 score group was significantly lower than in either the low-
score or negative categories (P <0.01 respectively), being posi-
tively correlated with the MI (Figure 5A). This correlation was
also found for early-stage (P <0.05) but not advanced tumours.
Bax immunoreactivity, showing a granular homogeneous cyto-
plasmic staining pattern (Figure 4B), demonstrated a markedly
patchy distribution in cancerlesions, with immunopositivity (score
.1) revealed in 41 of 82 (50.0%) cases. The average Bax immuno-
reactive score was 8 ± 4, (mean ± s.d., range 0-16), high values
(score .9) being exhibited by 8 of 40 (20%) early- and 12 of 44
(27.3%) advanced-stage lesions, and by 11 of58 (19.0%) differen-
tiated and 9 of 24 (37.5%) undifferentiated types. Both the overall
AI and MI values in the high Bax score group were higher than in
the negative group (Figure 5B, P =0.053, P <0.05 respectively),
whereas no association was noted on the basis of tumour-stage
category, including early and advanced stages. The finding for
correlations among AIs, MIs and immunopositivity for Bcl-2 and
Bax are summarized in Figure SC. An inverse correlation
regarding AIs and MIs between Bcl-2 and Bax positivity was
noted, the difference being significant (P <0.05, P <0.05 respec-
tively). Thus Al and MI values were low in Bcl-2 strong positive
cases whereas they were high in lesions demonstrating Bax
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immunoreactivity. However, there were no significant differences
in AIs and MIs between the group expressing one or the other of
the two immunohistochemical parameters and the group positive
for both (Figure 5C).
Survival
An early stage (36 early vs 42 advanced stage, P <0.01) and an
absence of lymph node metastasis (32 negative vs 46 positive
groups, P <0.01) were clearly associated with favourable outcome
(data not shown). However, there was no association between
survival rates and classification in terms of average values for
either AIs or MIs, immunoreactive scores for either Bcl-2 or Bax
or chemotherapy. Moreover, no correlation between lymph node
status and AIs, MIs or immunopositivity for Bcl-2 and Bax was
noted, with analysis of either all lesions or only advanced cases
(Table 1).
DISCUSSION
It is widely accepted that cells with a high proliferation activity or
after withdrawal oftrophic hormone stimulation in terminal differ-
entiated cases are very susceptible to apoptosis (Allan et al, 1987;
Ijiri et al, 1987; Walker et al, 1989). Strater et al (1995) reported
enterocytes undergoing apoptosis to be found frequently in the
proliferating zones and luminal surface mucosae in normal
colorectal epithelium. In colorectal adenomas, a clear positive
correlation between apoptotic and mitotic indices has been demon-
strated (Arai et al, 1995). In the present study, the AIs were closely
associated with the depth of tumour invasion in gastric carci-
nomas, in line with the results of our previous report using the in
situ DNA nick end labelling method (Saegusa et al, 1995a), but
showed no statistically significant relation to tumour differentia-
tion in contrast to the MI values. This study further demonstrated a
positive correlation between AIs and cell proliferation determined
by the MI, whereas no linkage between either of these indices and
the tumour size (lateral spreading diameter) was noted in early or
advanced stages. It is therefore suggested that tumour invasion
through the mucosa to the serosa may be more closely linked to
increased cell proliferative activity and propensity for apoptosis
than lateral spreading.
Bcl-2 and Bax are members of the group of proteins that regu-
late the apoptotic pathway. Sinicrope et al (1995) demonstrated
that colorectal carcinomas with a high percentage of cells
expressing Bcl-2 were significantly more likely to have low AIs
than those with low or absent Bcl-2. We previously indicated that
in Bcl-2-positive gastric carcinomas the apoptotic labelling index
is significantly lower in Bcl-2-positive foci than in Bcl-2-negative
foci, and the majority ofBcl-2-positive cancercells were in a non-
proliferating state using double immunostaining for Bcl-2 and
Ki-67 (Saegusa et al, 1995b). However, some studies have indi-
cated no dramatic difference in the apoptotic rate between Bcl-
2-negative and -positive tumours, suggesting that other control
mechanisms might also be involved (Wyllie et al, 1992; Sachs and
Lotem, 1993). Discrepancies could also be due to tumour hetero-
geneity, tissue specificity and evaluation methods for determining
apoptosis or Bcl-2 immunoreactivity.
It has been demonstrated that Bax acts as an accelerator
of apoptosis, opposing Bcl-2 effects on cell life (Oltvai et al,
1993). Krajewski et al (1994) proposed that the ratio of Bax to
Bcl-2 plays a critical role in regulating the relative propensity for
apoptosis. Recently, we demonstrated that Bcl-2 may be predomi-
nantly expressed at an early stage in gastric carcinomas, possibly
in negative association with p53 gene abnormalities (Saegusa et al,
1996). Texieria et al (1995) demonstrated that in human breast
cancer cell lines oestrogen (E2) depletion results in a marked
decrease in Bcl-2 expression but does not alter bax gene expres-
sion, suggesting that, in the absence of E2, the Bax/Bcl-2 ratio is
increased. In the present study, the finding that AIs in carcinomas
with high Bcl-2 immunolabelling scores were significantly lower
than in those with low scores or negative for Bcl-2 particularly in
early-stage tumours, in line with the MIs, together with the posi-
tive association with Bax immunoreactivity, supports the conclu-
sion that Bcl-2 and Bax are important regulatory proteins in cell
life. The possibility of a close linkage between the Bcl-2/Bax co-
expression pattern and progression was also demonstrated in
uterine cervical neoplasms (Saegusa et al, 1995c). Although some
studies have indicated the presence of mutant type bcl-2 and bax
genes (Pietenpol et al, 1994; Meijerink et al, 1995), further study is
needed to clarify their functional significance.
The prognostic significance of Bcl-2 expression in malignant
tumours has attracted the attention of several authors. It is appar-
ently correlated with a favourable prognosis in lung (Pezella et al,
1993) and breast cancers (Silvestrini et al, 1994), while not corre-
lating with pT stage, lymph node status and survival in gastric
carcinomas (Lauwers et al, 1995). In the latter other factors,
including depth of tumour invasion, tumour differentiation, lymph
node status, venous spread and whether curative or palliative
surgery is performed, may play an important role in determining
survival rates. Earlier studies have demonstrated that early-stage
gastric carcinomas with a high propensity for blood vessel inva-
sion and lymph node metastasis show a worse prognosis because
of early post-operative hepatic metastasis (Kodama et al, 1983;
Orita et al, 1992). Recently, Ranaldi et al (1995) reported that in
large early gastric cancers the presence of submucosal penetration
and lymph node metastasis shows a highly significant association
with a lower survival rate.
Considering the high incidence of AIs and MIs in the present
advanced-stage lesions, a possible relevance of apoptosis as prog-
nostic factor might have been expected. In our clinicopathological
analysis, however, a favourable prognosis was clearly associated
with an early stage and an absence of lymph node metastasis,
whereas no correlation with the Al, MI or expression ofBcl-2 and
Bax was revealed. In addition, lymph node status was not linked
with Al and MI values or Bcl-2/Bax expression, even in the
advanced category. We therefore speculate that the frequency of
apoptosis may not directly reflect biological behaviour, although
we cannot draw firm conclusions because of the relatively small
numberofcases examined. Shepherd et al (1988) showed no corre-
lation between Ki-67 scores and known prognostic parameters in
colorectal carcinomas, suggesting that the proliferative status has
no influence on the prognosis after surgical treatment alone.
In conclusion, the present study demonstrated that in gastric
carcinomas the propensity for apoptosis is closely associated with
cell proliferation and expression ofBcl-2 and Bax,but this appears
unlikely to have any important value as a prognostic factor.
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